News | July 01, 2022
H Clinical adds commercial home health capabilities for pharma industry
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Silo enters into commercial evaluation license agreement for next generation liposomes
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
Subscribe To Our Newsletter & Stay Updated
